These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

566 related items for PubMed ID: 18702970

  • 1. Metallothionein suppresses angiotensin II-induced nicotinamide adenine dinucleotide phosphate oxidase activation, nitrosative stress, apoptosis, and pathological remodeling in the diabetic heart.
    Zhou G, Li X, Hein DW, Xiang X, Marshall JP, Prabhu SD, Cai L.
    J Am Coll Cardiol; 2008 Aug 19; 52(8):655-66. PubMed ID: 18702970
    [Abstract] [Full Text] [Related]

  • 2. Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy.
    Cai L, Wang Y, Zhou G, Chen T, Song Y, Li X, Kang YJ.
    J Am Coll Cardiol; 2006 Oct 17; 48(8):1688-97. PubMed ID: 17045908
    [Abstract] [Full Text] [Related]

  • 3. Angiotensin II-induced p53-dependent cardiac apoptotic cell death: its prevention by metallothionein.
    Liu Q, Wang G, Zhou G, Tan Y, Wang X, Wei W, Liu L, Xue W, Feng W, Cai L.
    Toxicol Lett; 2009 Dec 15; 191(2-3):314-20. PubMed ID: 19808082
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. An angiotensin II type 1 receptor mutant lacking epidermal growth factor receptor transactivation does not induce angiotensin II-mediated cardiac hypertrophy.
    Zhai P, Galeotti J, Liu J, Holle E, Yu X, Wagner T, Sadoshima J.
    Circ Res; 2006 Sep 01; 99(5):528-36. PubMed ID: 16902180
    [Abstract] [Full Text] [Related]

  • 6. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction.
    Zhong J, Basu R, Guo D, Chow FL, Byrns S, Schuster M, Loibner H, Wang XH, Penninger JM, Kassiri Z, Oudit GY.
    Circulation; 2010 Aug 17; 122(7):717-28, 18 p following 728. PubMed ID: 20679547
    [Abstract] [Full Text] [Related]

  • 7. Angiotensin II plays a critical role in diabetic pulmonary fibrosis most likely via activation of NADPH oxidase-mediated nitrosative damage.
    Yang J, Tan Y, Zhao F, Ma Z, Wang Y, Zheng S, Epstein PN, Yu J, Yin X, Zheng Y, Li X, Miao L, Cai L.
    Am J Physiol Endocrinol Metab; 2011 Jul 17; 301(1):E132-44. PubMed ID: 21487074
    [Abstract] [Full Text] [Related]

  • 8. Cardiac metallothionein induction plays the major role in the prevention of diabetic cardiomyopathy by zinc supplementation.
    Wang J, Song Y, Elsherif L, Song Z, Zhou G, Prabhu SD, Saari JT, Cai L.
    Circulation; 2006 Jan 31; 113(4):544-54. PubMed ID: 16432057
    [Abstract] [Full Text] [Related]

  • 9. Metallothionein reverses the harmful effects of angiotensin II on the diabetic heart.
    De Mello WC.
    J Am Coll Cardiol; 2008 Aug 19; 52(8):667-9. PubMed ID: 18702971
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Metallothionein-I/II null cardiomyocytes are sensitive to Fusarium mycotoxin butenolide-induced cytotoxicity and oxidative DNA damage.
    Yang HY, Wang YM, Peng SQ.
    Toxicon; 2010 Jun 15; 55(7):1291-6. PubMed ID: 20144643
    [Abstract] [Full Text] [Related]

  • 13. Inactivation of GSK-3beta by metallothionein prevents diabetes-related changes in cardiac energy metabolism, inflammation, nitrosative damage, and remodeling.
    Wang Y, Feng W, Xue W, Tan Y, Hein DW, Li XK, Cai L.
    Diabetes; 2009 Jun 15; 58(6):1391-402. PubMed ID: 19324938
    [Abstract] [Full Text] [Related]

  • 14. Diabetes- and angiotensin II-induced cardiac endoplasmic reticulum stress and cell death: metallothionein protection.
    Xu J, Wang G, Wang Y, Liu Q, Xu W, Tan Y, Cai L.
    J Cell Mol Med; 2009 Aug 15; 13(8A):1499-512. PubMed ID: 19583814
    [Abstract] [Full Text] [Related]

  • 15. Chronic angiotensin II stimulation in the heart produces an acquired long QT syndrome associated with IK1 potassium current downregulation.
    Domenighetti AA, Boixel C, Cefai D, Abriel H, Pedrazzini T.
    J Mol Cell Cardiol; 2007 Jan 15; 42(1):63-70. PubMed ID: 17070838
    [Abstract] [Full Text] [Related]

  • 16. Metallothionein inhibits doxorubicin-induced mitochondrial cytochrome c release and caspase-3 activation in cardiomyocytes.
    Wang GW, Klein JB, Kang YJ.
    J Pharmacol Exp Ther; 2001 Aug 15; 298(2):461-8. PubMed ID: 11454906
    [Abstract] [Full Text] [Related]

  • 17. Pitavastatin, an HMG-CoA reductase inhibitor, exerts eNOS-independent protective actions against angiotensin II induced cardiovascular remodeling and renal insufficiency.
    Yagi S, Aihara K, Ikeda Y, Sumitomo Y, Yoshida S, Ise T, Iwase T, Ishikawa K, Azuma H, Akaike M, Matsumoto T.
    Circ Res; 2008 Jan 04; 102(1):68-76. PubMed ID: 17967781
    [Abstract] [Full Text] [Related]

  • 18. Metallothionein protects against doxorubicin-induced cardiomyopathy through inhibition of superoxide generation and related nitrosative impairment.
    Shuai Y, Guo JB, Peng SQ, Zhang LS, Guo J, Han G, Dong YS.
    Toxicol Lett; 2007 Apr 05; 170(1):66-74. PubMed ID: 17382496
    [Abstract] [Full Text] [Related]

  • 19. Attenuation of doxorubicin chronic toxicity in metallothionein-overexpressing transgenic mouse heart.
    Sun X, Zhou Z, Kang YJ.
    Cancer Res; 2001 Apr 15; 61(8):3382-7. PubMed ID: 11309296
    [Abstract] [Full Text] [Related]

  • 20. Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling.
    Weisberg AD, Albornoz F, Griffin JP, Crandall DL, Elokdah H, Fogo AB, Vaughan DE, Brown NJ.
    Arterioscler Thromb Vasc Biol; 2005 Feb 15; 25(2):365-71. PubMed ID: 15576638
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.